Sostos Inc

Sostos has developed a unique software technology that can identify personalized cancer treatment solutions for patients. Our Artificial Intelligence (AI) system is called CATOS - Cancer Treatment Optimization Solution. CATOS can scan large genomic and image datasets and predict the optimal approach for cancer screening, diagnosis, prognosis, and treatment. CATOS allows for a customized approach for an individual’s cancer, and the development of novel diagnostic assays for patients. The CATOS system has been proven to be effective and accurate for precision diagnostics, with 76 published scientific articles and more than 4,492 citations. The initial CATOS product, a 7-gene lung cancer assay (CATOS-LU), has been validated in 1,641 patients, including a randomized Phase III clinical trial. The FDA has classified CATOS-LU as a “Novel Technology” (under review). The CATOS software platform has over 53,000 browses, which will be upgraded for premium paid use. In addition, CATOS can be used for drug discovery, by identification of new cancer treatment options from drugs that are currently approved for use for other diseases, which can be safely repurposed for cancer treatment. Using our software, we have discovered and filed patents for 8 diagnostic assays and 21 ‘repurposed’ compounds.